Here is the blunt version: Zepbound and Mounjaro are the same drug, tirzepatide, from the same maker. Zepbound is approved for chronic weight management, Mounjaro is approved for type 2 diabetes. The molecule inside the pen is identical. So the weight loss you can expect is essentially the same, and the real decision is about labels, coverage, and which prescription path your situation allows.
That means most of the debate people have about zepbound vs mounjaro is a debate about paperwork, not pharmacology. It is worth understanding why, because getting the label wrong can cost weeks and hundreds of dollars.
Are they actually the same drug?
Yes, in the way that matters for effect. Both are tirzepatide, a single molecule that activates two gut hormone receptors, GIP and GLP-1. That dual action is the reason it tends to outperform older single-receptor drugs on weight, and the mechanism has been described in detail in the pharmacology literature on GLP-1 and dual GIP/GLP-1 receptor agonists. The prescribing information for Zepbound and for Mounjaro lists the same active ingredient and the same dose ladder, from 2.5 mg up to 15 mg weekly.
The difference is the approval. A drug company runs separate trials for separate uses and gets separate labels, sometimes under separate brand names, even when the substance is the same. Zepbound went through obesity trials and earned a weight management indication. Mounjaro went through diabetes trials and earned a type 2 diabetes indication. Same chemistry, two regulatory doors.
How much weight loss does tirzepatide produce?
The headline weight loss data comes from the Zepbound program. In SURMOUNT-1, published in 2022, adults with obesity but without diabetes lost roughly 15 to 21 percent of body weight across the doses over 72 weeks. You can read the SURMOUNT-1 results in full. The effect held up outside the original population too: SURMOUNT-CN, run in Chinese adults with obesity, reported substantial reductions on the same molecule.
Two other findings matter for expectations. SURMOUNT-4 tested what happens when treatment continues versus stops, and it showed that people who switched to placebo regained a large share of the weight while those who kept taking tirzepatide kept losing. The SURMOUNT-4 maintenance trial is a plain reminder that this is a long-term medication, not a short course. And a 2024 trial found tirzepatide reduced the severity of obstructive sleep apnea in people with obesity, which points to benefits beyond the number on the scale.
For readers weighing tirzepatide against semaglutide, a 2024 analysis comparing semaglutide and tirzepatide for weight loss found tirzepatide produced greater average weight reduction. That is a comparison worth knowing, though it does not change the point that Zepbound and Mounjaro are the same tirzepatide as each other.
So which label do you actually get?
This is where the honest answer stops being about the drug and starts being about your diagnosis.
| Question | Points toward Zepbound | Points toward Mounjaro |
|---|---|---|
| Do you have type 2 diabetes? | No | Yes |
| Goal on the prescription | Chronic weight management | Blood sugar control (weight loss follows) |
| On-label status for weight loss | On-label | Off-label |
| Coverage logic your plan uses | Weight management benefit | Diabetes benefit |
If you do not have diabetes and your goal is weight loss, Zepbound is the on-label choice and the one supported by the obesity trials. If you have type 2 diabetes, Mounjaro is the on-label choice for your condition, and the weight loss comes along because it is the same molecule. Trying to get Mounjaro for weight loss alone means asking a prescriber to write it off-label, and many plans will decline without a diabetes diagnosis.
Which one is cheaper?
Neither in any dependable way. Both list above a thousand dollars a month, and almost nobody pays list. Your real cost is decided by three things: whether your plan covers the relevant category, whether you qualify for a manufacturer savings card, and what the self-pay price is if coverage is denied.
Coverage is usually a category decision, not a brand decision. Plans that exclude anti-obesity medication will deny Zepbound regardless of medical necessity, while a plan with a diabetes benefit may cover Mounjaro readily for someone with diabetes. Savings cards are narrower than the ads suggest, since commercial copay assistance generally assumes existing commercial coverage and excludes people on Medicare or Medicaid.
When coverage falls through, cash payers compare the manufacturer self-pay program against compounded tirzepatide. Compounded tirzepatide is prepared by a compounding pharmacy and is not an FDA-approved product, which is a genuine distinction and not a footnote. Some supervised telehealth practices publish flat monthly pricing for that route; a plain rundown of the Zepbound vs Mounjaro for weight loss pricing paths can help before a first appointment, with prescribing handled by a licensed clinician rather than sold as a product. The trade is regulatory assurance for cost predictability, and whether it is reasonable belongs with a prescriber who knows the case.
What is not worth stressing over?
The pen color, the box, and long arguments over which brand is stronger. They are the same tirzepatide. There is no hidden potency advantage to chasing Mounjaro if you qualify for Zepbound, and no benefit to insisting on Zepbound if you have diabetes and Mounjaro is what your plan covers. Energy spent trying to game the brand name is usually better spent getting the prior authorization paperwork right, since that is where most delays actually live.
One thing genuinely on the horizon is worth a mention. An oral GLP-1 option, orforglipron, was studied for obesity and reported meaningful weight loss in the orforglipron obesity trial. A daily pill would change the convenience math for some people, but it does not change the fact that Zepbound and Mounjaro remain the same injectable molecule as each other today.
Key takeaways
- Zepbound and Mounjaro are both tirzepatide from the same maker; the molecule is identical.
- Zepbound is approved for weight management, Mounjaro for type 2 diabetes.
- Your diagnosis, not the brand, usually decides which label you can get covered.
- Compounded tirzepatide is not FDA-approved and is a separate route with its own trade-offs.
- SURMOUNT-4 shows the weight loss depends on staying on treatment.
See also: Installing a Sauna Heater: Electrical, Foundation, and Clearances on a Budget
Frequently asked questions
Are Zepbound and Mounjaro the same drug?
They contain the same active ingredient, tirzepatide, made by the same manufacturer. Zepbound is approved for chronic weight management, while Mounjaro is approved for type 2 diabetes. The molecule is identical; the label and the approved use differ.
If they are the same molecule, is one better for weight loss?
For weight loss specifically, Zepbound carries the approval and the obesity trial evidence. Mounjaro produces weight loss too because it is the same drug, but its studies were run in people with type 2 diabetes, so the on-label choice for weight management is Zepbound.
Can I get Mounjaro prescribed just for weight loss?
Prescribing Mounjaro purely for weight loss is off-label, since its approval is for type 2 diabetes. Many plans will only cover it with a diabetes diagnosis, which is why the coverage path, not the molecule, usually settles the question.
Which one is cheaper?
Neither is reliably cheaper. Both list above a thousand dollars a month. What you pay depends on whether your plan covers your diagnosis, whether you qualify for a savings card, and which self-pay program applies.
Is compounded tirzepatide the same as either brand?
No. Compounded tirzepatide is prepared by a compounding pharmacy and is not an FDA-approved product. It may contain the same molecule, but it has not gone through the approval process behind the brand trials.
